Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Leo W. Jenkins Cancer Center

Overview

This trial is designed to study the safety and efficacy of the combination of carboplatin, bevacizumab, and pelvic radiation therapy. Rationale for substituting cisplatin with carboplatin: Five landmark trials in cervical cancer prompted the National Cancer Institute in February of 1999 to issue a clinical announcement stating that "strong consideration should be given to adding concurrent chemotherapy in the treatment of invasive cervical cancer". The chemotherapeutic agent which was a common denominator to all 5 trials was cisplatin, and ever since it has become part of the standard of care for the treatment of stage IIB, III, and IVA cervical cancers. In addition, chemoradiotherapy with cisplatin is also considered one of the standard treatment options for IB2 and IIA tumors greater than 4 cm in diameter. The most recent Gynecologic Oncology Group protocols for cervical cancer have used cisplatin and radiation therapy as in two of the five landmark trials. However, the benefit in survival given by cisplatin has not been without toxicity. In summary, in the trial by Keys 35% of patients receiving cisplatin and radiotherapy experienced moderate or severe toxicities. In the one by Rose, only 49 % completed the intended 6 cycles of chemotherapy. Based on the toxicity profile of cisplatin, Higgins performed a phase II study of concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. He demonstrated the ability to administer carboplatin with concurrent radiation therapy with significantly less toxicity and with 94 % of the planned treatments delivered. A comprehensive analysis of the literature from 1998 which compared the efficacy of carboplatin versus cisplatin in solid tumors concluded that for ovarian cancer and lung cancer the effectiveness of carboplatin was comparable to cisplatin, while for germ cell tumors, bladder cancer, and head and neck cancer cisplatin appeared superior. There was no mention of cervical cancer in this review, since at present there is no phase III trial comparing carboplatin versus cisplatin in cervix cancer. Rationale for bevacizumab: Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of vascular endothelial growth factor (VEGF) which stimulates tumor and tumor blood vessel growth. Targeting VEGF with bevacizumab could potentially be of benefit in cervical cancer patients by starving the tumor's blood supply and potentially enhancing the effect of radiotherapy and carboplatin chemotherapy.

Five landmark trials in cervical cancer prompted the National Cancer Institute in February of 1999 to issue a clinical announcement stating that "strong consideration should be given to adding concurrent chemotherapy in the treatment of invasive cervical cancer". The chemotherapeutic agent which was a common denominator to all 5 trials was cisplatin, and ever since it has become part of the standard of care for the treatment of stage IIB, III, and IVA cervical cancers. In addition, chemoradiotherapy with cisplatin is also considered one of the standard treatment options for IB2 and IIA tumors greater than 4 cm in diameter. The most recent GOG protocols for cervical cancer have used cisplatin 40 mg/m2 on days 1, 8, 15, 22, 29 of radiation therapy and once during parametrial brachytherapy boost for a total of 6 cycles. This cisplatin schedule was used in 2 of the 5 landmark trials by Rose \[3\] and Keys \[4\], respectively. However, the benefit in survival given by cisplatin, has not been without toxicity. Note that in the trial reported by Rose there was no radiotherapy alone arm for comparison. In summary, in the trial by Keys 35% of patients experienced grade 3 (moderate) or grade 4 (severe) toxicities, compared with 13 % in the radiotherapy alone arm. Specifically, 21 % experienced grade 3 or 4 leukopenia. Similarly, in the one by Rose, 23 % experienced grade 3 or 4 leukopenia, and only 49.4 % completed the intended 6 cycles of chemotherapy. Based on the toxicity profile of cisplatin, Higgins et al. \[5\] performed a phase II study of concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. They demonstrated the ability to administer carboplatin dose based on an AUC of 2.0 on schedule with concurrent radiation therapy in the treatment of cervix cancer. Grade 3 leukopenia was observed in only 10 % of the patients, and no grade 4 leukopenia was observed. This is approximately half the incidence of leukopenia seen with cisplatin. More importantly, carboplatin was administered with an AUC of 2 in 175 out of 186 (94%) planned treatments. Treatment with carboplatin in this study had a similar excellent response rate, but with reduced hematologic side effects. A comprehensive analysis of the literature from 1998 which compared the efficacy of carboplatin versus cisplatin in solid tumors concluded that for ovarian cancer and lung cancer the effectiveness of carboplatin was comparable to cisplatin, while for germ cell tumors, bladder cancer, and head and neck cancer cisplatin appeared superior \[6\]. There was no mention of cervical cancer in this review, since at present there is no phase III trial comparing carboplatin versus cisplatin in cervix cancer. Targeted therapies Angiogenesis has been described in the majority of the cancer types affecting the female genital tract \[7-14\]. Multiple growth factors and cytokines are involved in the angiogenic process that accompanies cervical carcinogenesis. VEGF has a predominant role acting as an endothelial cell specific mitogen \[15-17\], and stimulates cell proliferation and increases vascular permeability. Various cancer types including breast, endometrial, ovarian, bladder, and lung cancer exhibit elevated VEGF expression at advanced stages \[18-25\], and has also been associated with high-grade intraepithelial lesions and cervical cancer \[26-32\]. VEGF protein levels have been shown to correlate with local tumor progression, metastasis and poor prognosis in the uterine cervix, based on immunohistochemical or enzyme immunoassay studies \[26-31\]. In patients undergoing primary radiotherapy for cervical cancer, serum VEGF influenced the progression free survival \[33\]. However, other reports have suggested that VEGF does not have a prognostic value \[32\]. In addition, Soufla et al. found a highly significant increase of VEGF mRNA expression upon cervical neoplastic transformation, and that high-grade squamous intraepithelial lesions exhibited higher VEGF mRNA levels than low-grade lesions \[34\]. Treatment of endothelial cells with carboplatin significantly increases the expression of VEGF \[35\]. Neutralization of secreted VEGF with specific polyclonal anti-VEGF antibodies sensitizes endothelial cells to carboplatin treatment and increases apoptosis several-fold \[35\]. Treatment with polyclonal anti-VEGF antibodies and carboplatin has been shown in vivo models to significantly enhance solid tumor growth inhibition over individual monotherapies \[35\]. Therefore, targeting VEGF could potentially be of benefit in cervical cancer patients. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of VEGF. Since bevacizumab may cause proteinuria and hypertension, carboplatin, which has less potential for renal toxicity than cisplatin, seems a better choice for combining with bevacizumab. The combination of radiotherapy, carboplatin, and bevacizumab could result in better results with decreased toxicity.

Interventions

BevacizumabDRUG

Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.

CarboplatinDRUG

Radiation TherapyRADIATION

Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks. Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have IB2 and IIA tumors greater than 4 cm in diameter, IIB, IIIB without hydronephrosis or non-functioning kidney, and IVA without invasion to the bladder or rectum, primary, previously untreated, and histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix. * Negative, non-suspicious para-aortic nodes determined by CT lymphangiogram, MRI or lymphadenectomy. * Adequate bone marrow function: ANC greater ≥ 1,500/mm3, platelets ≥ 100,000/mm3. * Adequate renal function: serum creatinine ≤ 1.5 mg/100 mL. * Adequate hepatic function: bilirubin less than or equal to 1.5 x upper limit of normal (ULN) and SGOT and alkaline phosphatase less than or equal to 3 x ULN. * Zubrod Performance Status of 0 or 1 * Patients of childbearing potential must have a negative serum pregnancy test within14 days of enrolling in this study and use an effective form of contraception during the study period. * Patients who are medically suitable for treatment with radical intent using concurrent chemotherapy and pelvic radiation. Exclusion Criteria: * Patients with Stage IA, IB1, IB2 and IIa tumors less than 4 cm in diameter, IIIA or IVB disease. * Patients who have known metastases to para-aortic or scalene nodes or metastases to other organs outside the radiation field at the time of the original clinical and surgical staging. * Extensive tumor preventing intracavitary irradiation. * Distal vaginal involvement or any disease such that an interstitial implant might be necessary * Previous pelvic or abdominal radiation, cytotoxic chemotherapy, or previous therapy of any kind for this malignancy. * Patients who might require an emergency surgical procedure to relieve hydronephrosis, or who are at risk of perforating the bladder and might require surgery. * Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields * Life expectancy of less than 12 weeks * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study. * Septicemia or severe infection * Patients who have circumstances that will not permit completion of this study or the required follow-up. * Patients who are pregnant at the time of diagnosis and do not wish pregnancy termination prior to initiation of treatment. * Other concomitant malignancies, with the exception of nonmelanoma skin cancer, who had (or have) any evidence of other cancer present within the last 5 years. * Bevacizumab-Specific Exclusions * Inadequately controlled hypertension (defined as systolic blood pressure \>150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications) * Any prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Grade II or greater congestive heart failure * Known CNS disease * Significant vascular disease (e.g., aortic aneurysm, aortic dissection) * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, ulcer, or bone fracture * Proteinuria at screening as demonstrated by either * Urine protein:creatinine (UPC) ratio ≥1.0 at screening OR * Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * Known hypersensitivity to any component of bevacizumab * Pregnant (positive pregnancy test) or lactating. Use of effective means of contraception (men and women) in subjects of child-bearing potential * Any history of stroke or transient ischemic attack at any time * History of myocardial infarction or unstable angina within 6 months of study enrollment * Carboplatin-Specific Exclusions * History of severe allergic reactions to cisplatin or other platinum-containing compounds. * Patients with severe bone marrow depression or significant bleeding.

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes